TOP TIERMARKET NEWSWIRE
News & sentiment

ACTUATE THERAPEUTICS Equity (ACTU) — News & AI sentiment

ACTUATE THERAPEUTICS Equity (ACTU) news roundup. 2 stories in the past week, 3 over 30 days. Average 30-day sentiment is 63.3/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
2
avg sentiment 61.5/100
30d stories
3
avg sentiment 63.3/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

ACTU news in the last 24 hours, 7 days, 30 days and 90 days

How much ACTU coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowACTU storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days261.5/100ACTU headlines →
Last 30 days363.3/100ACTU headlines →
Last 90 days658/100ACTU headlines →

Latest stories on ACTU

5d ago
5d ago
Actuate Therapeutics stock gets FDA clearance for elraglusib trial
Investing.com Analyst Ratings67 · bullishproduct/pr
Aug 18
Actuate Therapeutics stock initiated with buy rating at Rodman & Renshaw
Investing.com Analyst Ratings61 · neutralanalyst
Jul 30
Jul 17
Jun 24
Jun 9
Jun 1
May 22
Open ACTU in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →